UY26956A1 - Derivados del pirazol para el tratamiento de enfermedades virales - Google Patents
Derivados del pirazol para el tratamiento de enfermedades viralesInfo
- Publication number
- UY26956A1 UY26956A1 UY26956A UY26956A UY26956A1 UY 26956 A1 UY26956 A1 UY 26956A1 UY 26956 A UY26956 A UY 26956A UY 26956 A UY26956 A UY 26956A UY 26956 A1 UY26956 A1 UY 26956A1
- Authority
- UY
- Uruguay
- Prior art keywords
- formula
- compounds
- optionally substituted
- treatment
- indicates
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 102100034343 Integrase Human genes 0.000 abstract 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0024795.7A GB0024795D0 (en) | 2000-10-10 | 2000-10-10 | Pyrazole derivatives for the treatment of viral diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY26956A1 true UY26956A1 (es) | 2002-04-26 |
Family
ID=9900999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY26956A UY26956A1 (es) | 2000-10-10 | 2001-10-09 | Derivados del pirazol para el tratamiento de enfermedades virales |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6699887B2 (enExample) |
| EP (1) | EP1326843A1 (enExample) |
| JP (1) | JP4015548B2 (enExample) |
| KR (1) | KR100534158B1 (enExample) |
| CN (2) | CN1191239C (enExample) |
| AR (1) | AR030858A1 (enExample) |
| AU (2) | AU2165102A (enExample) |
| BR (1) | BR0114483A (enExample) |
| CA (1) | CA2423515A1 (enExample) |
| CZ (1) | CZ20031297A3 (enExample) |
| EC (1) | ECSP034547A (enExample) |
| GB (1) | GB0024795D0 (enExample) |
| GT (1) | GT200100201A (enExample) |
| HR (1) | HRP20030251A2 (enExample) |
| HU (1) | HUP0302722A2 (enExample) |
| IL (1) | IL154875A0 (enExample) |
| MA (1) | MA26951A1 (enExample) |
| MX (1) | MXPA03003070A (enExample) |
| NO (1) | NO20031615L (enExample) |
| NZ (1) | NZ524740A (enExample) |
| PA (1) | PA8530301A1 (enExample) |
| PE (1) | PE20020750A1 (enExample) |
| PL (1) | PL362918A1 (enExample) |
| RU (1) | RU2270832C2 (enExample) |
| UY (1) | UY26956A1 (enExample) |
| WO (1) | WO2002030907A1 (enExample) |
| YU (1) | YU27203A (enExample) |
| ZA (1) | ZA200302519B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2423868C (en) * | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| GB0113524D0 (en) * | 2001-06-04 | 2001-07-25 | Hoffmann La Roche | Pyrazole derivatives |
| MXPA05002004A (es) | 2002-09-26 | 2005-04-28 | Pfizer | Derivados de pirazol. |
| EP1546132A1 (en) * | 2002-09-26 | 2005-06-29 | Pfizer Limited | Pyrazole derivatives as reverse transcriptase inhibitors |
| US7230025B2 (en) | 2002-09-26 | 2007-06-12 | Pfizer, Inc. | Pyrazole derivatives |
| GB0223232D0 (en) * | 2002-10-07 | 2002-11-13 | Pfizer Ltd | Chemical compounds |
| GB0223234D0 (en) * | 2002-10-07 | 2002-11-13 | Pfizer Ltd | Chemical compounds |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| TW200423930A (en) * | 2003-02-18 | 2004-11-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitors |
| WO2004085406A1 (en) | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
| US7220772B2 (en) | 2003-09-05 | 2007-05-22 | Pfizer, Inc. | Pyrazole derivatives |
| DK2433943T3 (da) * | 2004-07-01 | 2013-12-16 | Daiichi Sankyo Co Ltd | Mellemprodukter til thienopyrazol-derivater med PDE7-inhibitorisk aktivitet |
| US20070005049A1 (en) * | 2005-06-30 | 2007-01-04 | Comben Richard H | Apparatus and Method of Treating Urinary Incontinence by Heating Urethra |
| CA2660031A1 (en) * | 2006-07-05 | 2008-01-10 | Pfizer Products Inc. | Pyrazole derivatives as cytochrome p450 inhibitors |
| DE602007013573D1 (de) | 2006-08-16 | 2011-05-12 | Hoffmann La Roche | Nicht-nukleosidische reverse-transkriptase-hemmer |
| GB0713479D0 (en) * | 2007-07-11 | 2007-08-22 | Syngenta Participations Ag | Substituted aromatic heterocyclic compounds as fungicides |
| AU2008340422B2 (en) | 2007-12-21 | 2014-06-19 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| GB0823000D0 (en) * | 2008-12-17 | 2009-01-28 | Syngenta Participations Ag | Isothiazole and pyrazole derivatives with plant growth regulating properties |
| KR20110131190A (ko) | 2009-02-25 | 2011-12-06 | 다이이찌 산쿄 가부시키가이샤 | 3 고리성 피라졸로피리미딘 유도체 |
| FR2951549B1 (fr) | 2009-10-15 | 2013-08-23 | Olivier Schussler | Procede d'obtention de bioprotheses medicales implantables |
| JP5701884B2 (ja) | 2010-08-23 | 2015-04-15 | 第一三共株式会社 | 三環性ピラゾロピリミジン誘導体の結晶 |
| BR112013004258A2 (pt) | 2010-08-23 | 2016-08-02 | Daiichi Sankyo Co Ltd | cristal, composição farmacêutica, e, agente anticâncer |
| US9695127B2 (en) | 2012-11-08 | 2017-07-04 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compounds for treating HIV and methods for using the compounds |
| US9925190B2 (en) | 2015-02-16 | 2018-03-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecules targeting HIV-1 Nef |
| WO2019189731A1 (ja) | 2018-03-30 | 2019-10-03 | 住友化学株式会社 | 複素環化合物及びそれを含有する有害節足動物防除組成物 |
| US20220380341A1 (en) * | 2018-10-18 | 2022-12-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Inhibitors of hiv-1 nef for the treatment of hiv disease |
| FR3121927B1 (fr) | 2021-04-19 | 2023-03-31 | Eiffage Genie Civil Terrassement | Procédé d’inertage des boues d’excavation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993015060A1 (fr) | 1992-01-22 | 1993-08-05 | Nissan Chemical Industries, Ltd. | Derive de pyrazole substitue et bactericide agrohorticole |
| DK0674624T3 (da) * | 1992-12-17 | 1999-09-13 | Pfizer | Pyrazoler med CRF-antagonistisk aktivitet |
| US6005109A (en) | 1997-10-30 | 1999-12-21 | Pflizer Inc. | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
| KR100190730B1 (ko) * | 1992-12-17 | 1999-06-01 | 디. 제이. 우드, 스피겔 알렌 제이 | 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸 |
| TW336932B (en) * | 1992-12-17 | 1998-07-21 | Pfizer | Amino-substituted pyrazoles |
| WO2006027423A1 (fr) * | 2004-08-09 | 2006-03-16 | Simag Developpement | Dispositif de saisie comportant un capteur optique suivi d’un moyen de filtrage |
-
2000
- 2000-10-10 GB GBGB0024795.7A patent/GB0024795D0/en not_active Ceased
-
2001
- 2001-09-20 US US09/956,656 patent/US6699887B2/en not_active Expired - Fee Related
- 2001-10-04 CN CNB018171710A patent/CN1191239C/zh not_active Expired - Fee Related
- 2001-10-04 CN CNA2005100088329A patent/CN1680333A/zh active Pending
- 2001-10-04 CZ CZ20031297A patent/CZ20031297A3/cs unknown
- 2001-10-04 RU RU2003112610/04A patent/RU2270832C2/ru not_active IP Right Cessation
- 2001-10-04 PL PL01362918A patent/PL362918A1/xx not_active Application Discontinuation
- 2001-10-04 EP EP01986680A patent/EP1326843A1/en not_active Withdrawn
- 2001-10-04 JP JP2002534293A patent/JP4015548B2/ja not_active Expired - Fee Related
- 2001-10-04 AU AU2165102A patent/AU2165102A/xx active Pending
- 2001-10-04 YU YU27203A patent/YU27203A/sh unknown
- 2001-10-04 KR KR10-2003-7004984A patent/KR100534158B1/ko not_active Expired - Fee Related
- 2001-10-04 HU HU0302722A patent/HUP0302722A2/hu unknown
- 2001-10-04 WO PCT/EP2001/011474 patent/WO2002030907A1/en not_active Ceased
- 2001-10-04 MX MXPA03003070A patent/MXPA03003070A/es active IP Right Grant
- 2001-10-04 IL IL15487501A patent/IL154875A0/xx unknown
- 2001-10-04 HR HR20030251A patent/HRP20030251A2/hr not_active Application Discontinuation
- 2001-10-04 CA CA002423515A patent/CA2423515A1/en not_active Abandoned
- 2001-10-04 NZ NZ524740A patent/NZ524740A/en unknown
- 2001-10-04 BR BR0114483-9A patent/BR0114483A/pt not_active Application Discontinuation
- 2001-10-04 AU AU2002221651A patent/AU2002221651B2/en not_active Ceased
- 2001-10-05 PE PE2001000993A patent/PE20020750A1/es not_active Application Discontinuation
- 2001-10-05 AR ARP010104697A patent/AR030858A1/es not_active Application Discontinuation
- 2001-10-09 PA PA20018530301A patent/PA8530301A1/es unknown
- 2001-10-09 UY UY26956A patent/UY26956A1/es not_active Application Discontinuation
- 2001-10-09 GT GT200100201A patent/GT200100201A/es unknown
-
2003
- 2003-03-31 ZA ZA200302519A patent/ZA200302519B/en unknown
- 2003-04-07 MA MA27096A patent/MA26951A1/fr unknown
- 2003-04-08 EC EC2003004547A patent/ECSP034547A/es unknown
- 2003-04-09 NO NO20031615A patent/NO20031615L/no unknown
-
2004
- 2004-01-27 US US10/766,712 patent/US7183296B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP034547A (es) | Derivados de pirazol para el tratamiento de enfermedades virales | |
| AR009052A1 (es) | Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| ECSP034563A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos | |
| AR035792A1 (es) | Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo | |
| AR033499A1 (es) | Derivado de quinazolina, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para usar en la produccion de un efecto antiangeogenico y/o reductor de la permeabilidad vascular en un animal de sangre caliente | |
| BR0308816A (pt) | Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas | |
| ECSP034897A (es) | Nucleosidos 4'-sustituidos | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| UY28578A1 (es) | Derivados de amida | |
| CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
| GT200400116A (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades. | |
| AR055369A1 (es) | Compuestos derivados de xantina, su uso para preparar un medicamento para el tratamiento de una enfermedad mediada por el receptor hm74a, formulaciones y combinacion farmaceuticas que la comprenden y metodo de preparacion de los mismos | |
| AR003440A1 (es) | Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados. | |
| CL2004000590A1 (es) | Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v | |
| AR123685A1 (es) | Antagonistas del mrgx2 | |
| ES2038172T3 (es) | Procedimiento para preparar carboxamidas heterociclicas. | |
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| BRPI0607600A2 (pt) | derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina | |
| CO2024017138A2 (es) | Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas | |
| GT200100111A (es) | Derivados de pirrol | |
| CL2003002565A1 (es) | Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci | |
| BR0210158A (pt) | Derivados de pirazol como inibidores da transcriptase reversa do hiv | |
| CL2025000120A1 (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b. | |
| UY29823A1 (es) | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20141217 |